ArticleNeuroImage. Clinical2018
Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.
Article in NeuroImage. Clinical, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.Neurology · 2022Pooled it
- Localised grey matter atrophy in multiple sclerosis is network-based: a coordinate-based meta-analysis.Clinical radiology · 2019Pooled it
- Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Trial
- Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.Neurology · 2024Trial
- Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.Stem cell research & therapy · 2024Trial
- Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.Journal of neurology, neurosurgery, and psychiatry · 2021Trial
- Source-based morphometry analyses yield associations between large-scale structural brain networks and psychopathic traits in incarcerated adolescents.Frontiers in psychology · 2026Article
- Structural Cerebellar and Lateral Frontoparietal Networks are altered in CUD: An SBM Analysis.Addiction biology · 2025Article
- Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.Neurology · 2025Article
- Real-world brain volumetry in multiple sclerosis: importance of methodological consistency and clinical relevance of gray matter atrophy.Frontiers in neurology · 2025Article
- Assessing the role of volumetric brain information in multiple sclerosis progression.Computational and structural biotechnology journal · 2025Article
- Relationship between brain white matter damage and grey matter atrophy in hereditary spastic paraplegia types 4 and 5.European journal of neurology · 2024Article
- Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.Journal of neurology · 2024Article
- The thalamic covariance network is associated with cognitive deficits in patients with cerebral small vascular disease.Annals of clinical and translational neurology · 2024Article
- U-fiber diffusion kurtosis and susceptibility characteristics in relapsing-remitting multiple sclerosis may be related to cognitive deficits and neurodegeneration.European radiology · 2024Article
- Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosis.Brain communications · 2024Article
- Links between Neuroanatomy and Neurophysiology with Turning Performance in People with Multiple Sclerosis.Sensors (Basel, Switzerland) · 2023Article
- Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.Neurology · 2023Article
- Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.PloS one · 2023Article
- Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.Annals of neurology · 2022Observational
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate spatial patterns of gray matter (GM) atrophy and their association with disability progression in patients with early relapsing-remitting multiple sclerosis (MS) in a longitudinal setting.
methodsBrain MRI and clinical neurological assessments were obtained in 152 MS patients at baseline and after 10 years of follow-up. Patients were classified into those with confirmed disability progression (CDP) (
resultsThe identified patterns generally included structurally or functionally related GM regions. No significant differences were detected at baseline GM volume between the sub-groups. Over the follow-up, patients with CDP experienced a significantly greater rate of GM atrophy within two of the eight patterns, after correction for multiple comparisons (corrected
conclusionSBM analysis offers a novel way to study the temporal evolution of regional GM atrophy. Over 10 years of follow-up, disability progression in MS is related to GM atrophy in areas associated with motor and cognitive functioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.